股票骗局有哪些-中信证券app-【东方资本】,a股交易t 几,t0开通条件,专业线上配资

<pre id="uywai"><bdo id="uywai"></bdo></pre>

<strike id="uywai"></strike>

<center id="uywai"><delect id="uywai"></delect></center>

<dl id="uywai"></dl>

<input id="uywai"></input>

科學(xué)文獻(xiàn)

我們與學(xué)術(shù)機(jī)構(gòu)開展合作研究，以評(píng)估我們的管線產(chǎn)品。以下是發(fā)表的相關(guān)文獻(xiàn)。

年：

Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to PI, IMiD and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice

MV Mateos, K Weisel, T Martin, JG. Berdeja, A Jakubowia […]

Five?year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR?B38M chimeric antigen receptor T cells in the LEGEND?2 study: a case report

BY Wang, WH Zhao, YX Chen, XM Cao, Y Yang, YL Zhang, FX […]

Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice

Delforge M, Vekemans M, Depaus J, Meuleman N, Van De Ve […]

Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma

Tom Martin, Saad Z. Usmani, Jordan M. Schecter, Tito Ro […]

Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study

Adam D. Cohen, Parameswaran Hari, Myo Htut, Jesus G. Be […]

本網(wǎng)站使用Cookies來改善您的整體體驗(yàn)，讓您下次訪問網(wǎng)站時(shí)更加輕松快捷，為您帶來更好的服務(wù)。具體內(nèi)容請(qǐng)參閱隱私政策 Cookie政策。

<menu id="q8kwe"></menu>

<noframes id="q8kwe"><dl id="q8kwe"></dl></noframes>

<fieldset id="q8kwe"><tr id="q8kwe"></tr></fieldset>

<menu id="q8kwe"><xmp id="q8kwe"></xmp></menu>

<menu id="q8kwe"></menu>